GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity: Cell Cycle Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000079 describes any process that modulates the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity.
• CDKs are activated by cyclin binding and phosphorylation, and inhibited by CKIs and phosphatases such as PP2A.
• Dysregulation of CDK activity drives cancer, making CDKs and their regulators major therapeutic targets.
• CDK1 is now recognized as more than a cell cycle regulator, with roles in transcription, metabolism and DNA repair.
• CDK20/LF2 activates CDKL5 to control flagellar length, illustrating non-canonical CDK regulation.
• CRISPR knockout, point mutation, knock-in and overexpression models are essential to dissect CDK regulatory networks.
Description
Regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0000079) is a fundamental biological process that controls the timing and amplitude of CDK signaling, which is central to cell cycle progression, transcription, and differentiation. CDKs are serine/threonine kinases that require association with cyclin subunits for activation, and their activity is further modulated by activating and inhibitory phosphorylations, binding of CDK inhibitors (CKIs), and dephosphorylation by phosphatases. Because CDKs phosphorylate the retinoblastoma protein (RB) and other key substrates, their regulation is directly linked to cell proliferation and genome stability. Dysregulated CDK activity is a hallmark of cancer, and small-molecule CDK inhibitors have entered clinical trials, underscoring the importance of understanding this regulatory process. Moreover, CDKs such as CDK1 have non-canonical functions beyond the cell cycle, including regulation of transcription and metabolism, expanding the scope of GO:0000079. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of the mechanisms, genes, and experimental models relevant to GO:0000079.
regulation of cyclin-dependent protein serine/threonine kinase activity At A Glance
| GO ID | GO:0000079 |
|---|---|
| GO term | regulation of cyclin-dependent protein serine/threonine kinase activity |
| Ontology | biological_process |
| Synonym | regulation of CDK activity; regulation of cyclin-dependent protein kinase activity |
| Major function | Modulates the frequency, rate or extent of CDK catalytic activity, thereby controlling cell cycle progression, transcription, and differentiation. |
| Key regulators | Cyclins (e.g., CCNA2, CCNB1, CCNE1), CDK inhibitors (e.g., CDKN1A/p21, CDKN1B/p27), phosphatases (e.g., PP2A), and kinases (e.g., CDK7, WEE1). |
| Disease relevance | Cancer, cardiomyocyte hypertrophy, and developmental disorders. |
| Therapeutic targeting | CDK inhibitors are in clinical trials for cancer; CDK7 inhibitors are patented. |
What Is GO:0000079?
GO:0000079 is defined as any process that modulates the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity. In practice, this includes the binding of cyclins to CDKs, phosphorylation events that activate or inhibit CDK catalytic activity, interactions with CDK inhibitors (CKIs), and dephosphorylation by protein phosphatases. The term encompasses both positive and negative regulation, ensuring that CDK activity is precisely controlled in response to cellular signals.
Why Is regulation of cyclin-dependent protein serine/threonine kinase activity Important in Cell Biology?
Precise regulation of CDK activity is essential for normal cell division and genome integrity. When this regulation fails, uncontrolled proliferation, chromosomal instability, and cancer can result. Understanding GO:0000079 provides mechanistic insights into how cells coordinate growth signals with cell cycle entry and exit, and it informs the development of targeted therapies that inhibit specific CDKs or their regulators.
• Controls cell cycle transitions, ensuring ordered DNA replication and mitosis.
• Dysregulation leads to cancer, making CDKs and their regulators prime therapeutic targets.
• CDK inhibitors such as p27 (CDKN1B) are involved in cardiomyocyte hypertrophy.
• CDK1 has non-canonical roles in transcription, metabolism, and DNA repair.
• CDK20/LF2 activates CDKL5 to regulate flagellar length, linking CDK regulation to ciliary biology.
• Phosphatases like PP2A reverse CDK phosphorylation, providing an additional layer of control.
• Small-molecule CDK inhibitors are being developed based on structural insights into the ATP-binding pocket.
• CDK7 inhibitors are under patent protection for cancer therapy.
What Happens During regulation of cyclin-dependent protein serine/threonine kinase activity?
Cyclin Binding and CDK Activation
In simple terms: Cyclins are proteins that attach to CDKs and switch them on.
The primary step in CDK regulation is the binding of a cyclin subunit to the CDK catalytic core. This interaction induces conformational changes that align the ATP-binding site and substrate pocket, enabling phosphoryl transfer. Different cyclins pair with specific CDKs at distinct cell cycle phases: cyclin D with CDK4/6 in G1, cyclin E with CDK2 at G1/S, cyclin A with CDK2 in S phase, and cyclin B with CDK1 at mitosis. The abundance of cyclins is tightly controlled by transcription and ubiquitin-mediated proteolysis, providing a layer of regulation.
Activating and Inhibitory Phosphorylation
In simple terms: Adding phosphate groups to CDKs can either turn them on or off.
Full activation of CDKs requires phosphorylation of a conserved threonine residue in the T-loop by CDK-activating kinase (CAK), which in metazoans is composed of CDK7, cyclin H, and MAT1. Conversely, phosphorylation of inhibitory residues (Thr14 and Tyr15) by WEE1 and MYT1 kinases keeps CDKs inactive until dephosphorylation by CDC25 phosphatases. This dual phosphorylation system ensures that CDK activity is switched on only when conditions are favorable.
CDK Inhibitors (CKIs)
In simple terms: Inhibitor proteins bind to CDKs and block their activity.
CKIs fall into two families: the INK4 family (p16INK4a, p15INK4b, p18INK4c, p19INK4d) that specifically inhibits CDK4/6, and the CIP/KIP family (p21CIP1, p27KIP1, p57KIP2) that broadly inhibits CDK2, CDK1, and CDK4/6. These inhibitors are regulated by transcription, phosphorylation, and degradation, and they mediate cell cycle arrest in response to DNA damage, growth factor withdrawal, or differentiation signals. For example, p27 (CDKN1B) is regulated by SGK1 in cardiomyocyte hypertrophy.
Dephosphorylation by Protein Phosphatases
In simple terms: Phosphatases remove phosphate groups from CDKs, reversing activation.
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that counteracts CDK phosphorylation. PP2A can dephosphorylate CDK substrates and regulatory sites, thereby terminating CDK signaling. The balance between kinase and phosphatase activities determines the net phosphorylation state of CDK targets, such as RB, and thus controls cell cycle progression.
Non-Canonical Regulation and CDK20/LF2
In simple terms: Some CDKs are activated by unusual partners, not just cyclins.
CDK20 (also known as CCRK) and its partner LF2 can activate CDKL5, a ciliary kinase, to control flagellar length. This demonstrates that CDK regulation extends beyond the classical cyclin-CDK paradigm and can involve tissue-specific or organelle-specific mechanisms. Such non-canonical regulation highlights the diversity of processes encompassed by GO:0000079.
Key Genes Involved in GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
The following genes encode core components and regulators of cyclin-dependent protein serine/threonine kinase activity, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDK1 | Catalytic subunit of the mitotic CDK; phosphorylates substrates for mitosis | Essential for cell cycle progression; non-canonical roles in transcription and metabolism |
| CDK2 | Controls G1/S transition and S phase progression | Target in cancer; regulated by cyclin E and p27 |
| CDK4 | Phosphorylates RB in early G1 | Target of INK4 inhibitors; frequently dysregulated in cancer |
| CDK6 | Similar to CDK4; promotes G1 progression | Target in cancer and leukemia |
| CDK7 | CDK-activating kinase (CAK) subunit; phosphorylates CDKs | Inhibitors in clinical trials; patent landscape reviewed |
| CCNA2 | Cyclin A; activates CDK2 and CDK1 | Regulates S phase and mitosis |
| CCNB1 | Cyclin B; activates CDK1 at mitosis | Key mitotic regulator |
| CCNE1 | Cyclin E; activates CDK2 at G1/S | Overexpressed in cancers |
| CDKN1A | p21; CIP/KIP inhibitor of CDKs | Mediates p53-dependent cell cycle arrest |
| CDKN1B | p27; CIP/KIP inhibitor; regulated by SGK1 | Involved in cardiomyocyte hypertrophy |
| CDKN2A | p16INK4a; inhibits CDK4/6 | Tumor suppressor frequently mutated in cancer |
| WEE1 | Kinase that phosphorylates CDK1 at Tyr15 | Target for cancer therapy |
| CDC25C | Phosphatase that activates CDK1 by removing inhibitory phosphate | Regulates mitotic entry |
| PPP2CA | Catalytic subunit of PP2A; dephosphorylates CDKs and substrates | Counteracts CDK signaling |
| CDK20 | Activates CDKL5 in ciliary regulation | Non-canonical CDK regulation |
| CDKL5 | Ciliary kinase activated by CDK20/LF2 | Controls flagellar length |
| RB1 | Retinoblastoma protein; substrate of CDK4/6 and CDK2 | Key downstream effector of CDK regulation |
How Is regulation of cyclin-dependent protein serine/threonine kinase activity Regulated?
The regulation of CDK activity is itself subject to multiple layers of control. Upstream signaling pathways, including growth factor receptors and the PI3K/AKT/mTOR axis, modulate cyclin expression and CKI stability. The SGK1 kinase regulates p27 (CDKN1B) in cardiomyocyte hypertrophy, illustrating hormone-sensitive control. Protein phosphatases such as PP2A provide reversible dephosphorylation, ensuring that CDK signaling can be rapidly terminated. Additionally, the CDK-activating kinase CDK7 is itself regulated by phosphorylation and interaction with cyclin H and MAT1. These interconnected mechanisms ensure that CDK activity is precisely tuned to cellular context.
regulation of cyclin-dependent protein serine/threonine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDK4 | Breast cancer, liposarcoma | Knockout or point-mutation in cancer cell lines; xenograft models |
| CDK7 | Cancer (transcription addiction) | Knockout and inhibitor-resistant knock-in models |
| CDKN1B | Cardiomyocyte hypertrophy | Cardiomyocyte-specific knockout or overexpression |
| CDKL5 | CDKL5 deficiency disorder | Knock-in of patient mutations in iPSC-derived neurons |
| RB1 | Retinoblastoma, osteosarcoma | Knockout in retinal organoids or cancer cells |
Cancer
Dysregulation of CDK activity is a hallmark of cancer. Overexpression of cyclins (e.g., CCND1, CCNE1) or loss of CKIs (e.g., p16, p27) leads to hyperactive CDKs, uncontrolled proliferation, and tumorigenesis. CDK4/6 inhibitors such as palbociclib have been approved for breast cancer, and CDK7 inhibitors are in development. Structural studies have guided the design of ATP-competitive inhibitors that target the CDK active site.
Cardiovascular Disease
In cardiomyocyte hypertrophy, SGK1-sensitive regulation of p27 (CDKN1B) modulates CDK activity, linking GO:0000079 to cardiac remodeling. This suggests that targeting CDK regulation could have therapeutic potential in heart disease.
Developmental and Ciliary Disorders
CDK20/LF2-mediated activation of CDKL5 controls flagellar length, and mutations in CDKL5 cause neurodevelopmental disorders such as CDKL5 deficiency disorder. This highlights the importance of non-canonical CDK regulation in development and disease.
From regulation of cyclin-dependent protein serine/threonine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CDK2 impair cell cycle progression? | CRISPR knockout of CDK2 in human cell lines |
| Does a specific CDK4 mutation confer resistance to inhibitors? | Point mutation knock-in of CDK4 in cancer cells |
| How does CDK7 phosphorylation of CDK1 affect mitosis? | Knock-in of phospho-mimetic or phospho-dead CDK1 |
| What is the role of p27 in cardiomyocyte hypertrophy? | Overexpression or knockout of CDKN1B in cardiomyocytes |
| Does CDK20/LF2 activate CDKL5 in cilia? | Knockout of CDK20 or CDKL5 in flagellated cells |
| How does PP2A regulate CDK substrates? | Knockout or knockdown of PPP2CA followed by phosphoproteomics |
How to Study the regulation of cyclin-dependent protein serine/threonine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript levels of CDKs, cyclins, CKIs | Expression profiling in cancer vs normal |
| Phosphoproteomics | Global phosphorylation sites | Identifying CDK substrates and PP2A targets |
| In vitro kinase assay | Catalytic activity of CDK-cyclin complexes | Testing inhibitors or mutations |
| Western blot | Phosphorylation status of RB, CDK1 | Cell cycle analysis |
| Flow cytometry | DNA content and cell cycle distribution | Assessing proliferation after CDK perturbation |
| Live-cell imaging | CDK activity biosensors | Real-time dynamics in single cells |
| CRISPR screen | Gene essentiality and synthetic lethality | Identifying regulators of CDK activity |
Genomic and Transcriptomic Profiling
RNA-seq and single-cell RNA-seq can quantify expression of cyclins, CDKs, and CKIs across conditions, revealing transcriptional regulation of GO:0000079. CRISPR screens coupled with RNA-seq can identify genes that modulate CDK activity.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based phosphoproteomics identifies CDK substrates and phosphorylation sites, providing a global view of CDK signaling output. This is particularly useful for understanding how phosphatases like PP2A counteract CDK activity.
Functional Assays for CDK Activity
In vitro kinase assays using recombinant CDK-cyclin complexes and peptide substrates measure catalytic activity directly. Cell-based assays, such as RB phosphorylation and EdU incorporation, report on CDK function in vivo.
Imaging and Live-Cell Analysis
Fluorescent biosensors and live-cell imaging can track CDK activity dynamics in real time, revealing spatial and temporal regulation. For ciliary CDKs, high-resolution imaging of flagella can assess CDK20/CDKL5 function.
How CRISPR Can Be Used to Study GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
Knockout
CRISPR knockout of CDKs, cyclins, or CKIs is used to determine their requirement for cell cycle progression and to identify synthetic lethal interactions. For example, knockout of CDK2 in cancer cells can reveal dependencies.
Point Mutation
Point mutations can be introduced to mimic or abolish phosphorylation sites, such as CDK1 T14/Y15 or CDK7 T-loop phosphorylation, to dissect regulatory mechanisms. Inhibitor-resistance mutations in CDK4/6 are also modeled by point mutation.
Knock-in
Knock-in of tagged CDKs (e.g., GFP or HA) allows for affinity purification and proteomic analysis of CDK complexes. Knock-in of disease-associated mutations, such as in CDKL5, enables functional studies in relevant cell types.
Overexpression
Overexpression of cyclins or CDKs can drive uncontrolled proliferation and is used to model oncogenic transformation. Conversely, overexpression of CKIs like p27 can induce cell cycle arrest.
How EDITGENE Supports regulation of cyclin-dependent protein serine/threonine kinase activity Research
Researchers studying regulation of cyclin-dependent protein serine/threonine kinase activity-related genes often need to determine whether a candidate gene is causally involved in CDK regulation, cell cycle control, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for regulation of cyclin-dependent protein serine/threonine kinase activity research.
Frequently Asked Questions About regulation of cyclin-dependent protein serine/threonine kinase activity
What is GO:0000079?
GO:0000079 is the Gene Ontology term for regulation of cyclin-dependent protein serine/threonine kinase activity, encompassing any process that modulates the frequency, rate or extent of CDK activity.
What genes are involved in regulation of cyclin-dependent protein serine/threonine kinase activity?
Key genes include CDK1, CDK2, CDK4, CDK6, CDK7, cyclins (CCNA2, CCNB1, CCNE1), CDK inhibitors (CDKN1A, CDKN1B, CDKN2A), WEE1, CDC25C, and PPP2CA.
How is CDK activity regulated?
CDK activity is regulated by cyclin binding, activating and inhibitory phosphorylation, CDK inhibitors, and dephosphorylation by phosphatases like PP2A.
Why is regulation of CDK activity important in cancer?
Dysregulated CDK activity drives uncontrolled proliferation; CDK inhibitors are used in cancer therapy.
What is the role of CDK7 in CDK regulation?
CDK7 is the catalytic subunit of CDK-activating kinase (CAK), which phosphorylates CDKs to activate them.
How does p27 regulate CDK activity?
p27 (CDKN1B) is a CIP/KIP inhibitor that binds and inhibits CDK-cyclin complexes; its regulation by SGK1 is linked to cardiomyocyte hypertrophy.
What experimental models are used to study CDK regulation?
CRISPR knockout, point mutation, knock-in, and overexpression models in cell lines and animal models are commonly used.
What is the connection between CDK20 and CDKL5?
CDK20/LF2 activates CDKL5 to control flagellar length, representing non-canonical CDK regulation.
How does PP2A regulate CDK activity?
PP2A is a phosphatase that dephosphorylates CDK substrates and regulatory sites, counteracting CDK signaling.
What methods are used to measure CDK activity?
In vitro kinase assays, phosphoproteomics, Western blot for RB phosphorylation, and live-cell biosensors are used.
Conclusion
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity is a central biological process that governs cell cycle progression, transcription, and differentiation. Its dysregulation is implicated in cancer, cardiovascular disease, and developmental disorders. Understanding the molecular mechanisms, key genes, and regulatory layers of CDK activity is essential for both basic research and therapeutic development. CRISPR-based models, combined with advanced omics and imaging, provide powerful tools to dissect this process and identify new drug targets.
References
- 1. Otto T et al.. 2017. Cell cycle proteins as promising targets in cancer therapy.. Nat Rev Cancer 17(2):93-115 PMID: 28127048
- 2. Kovalová M et al.. 2023. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).. Expert Opin Ther Pat 33(2):67-87 PMID: 36975020
- 3. Davies TG et al.. 2002. Structure-based design of cyclin-dependent kinase inhibitors.. Pharmacol Ther 93(2-3):125-33 PMID: 12191605
- 4. Hou Y et al.. 2025. Activation of the ciliary kinase CDKL5 is mediated by the cyclin-dependent kinase CDK20/LF2 to control flagellar length.. PLoS Biol 23(12):e3003560 PMID: 41385589
- 5. Voelkl J et al.. 2015. SGK1-Sensitive Regulation of Cyclin-Dependent Kinase Inhibitor 1B (p27) in Cardiomyocyte Hypertrophy.. Cell Physiol Biochem 37(2):603-14 PMID: 26344141
- 6. Millward TA et al.. 1999. Regulation of protein kinase cascades by protein phosphatase 2A.. Trends Biochem Sci 24(5):186-91 PMID: 10322434
- 7. Adams PD. 2001. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks.. Biochim Biophys Acta 1471(3):M123-33 PMID: 11250068
- 8. Massacci G et al.. 2023. The Cyclin-dependent kinase 1: more than a cell cycle regulator.. Br J Cancer 129(11):1707-1716 PMID: 37898722
